To do so, we generated RNA-sequencing data from IDH-mutant astrocytomas included in the CATNON randomised phase III clinical trial and combined it with additional multi-domain high-throughput data, along with multi-omics data from GLASS-NL and TCGA. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).